- Investor's Business Daily•7 days ago
Pfizer and Tesaro could follow AstraZeneca which, early Friday, unveiled strong results from a trial of Lynparza in breast cancer.
- Motley Fool•8 days ago
The approval of Valeant's new psoriasis drug Siliq is good news, but investors will want to temper their expectations for the drug.
- American City Business Journals•11 days ago
Drug company Pharmacyclics made the highest amount of non-research payments out of the more than $9 million in payments received by 25 Chicago-area doctors in 2015. Sunnyvale, California-based Pharmacyclics, ...
AZN.BA : Summary for ASTRAZENECA CEDEAR EACH REP 0.5 - Yahoo Finance
ASTRAZENECA CEDEAR EACH REP 0.5 (AZN.BA)
Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
At close: 12:08PM ART
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|